Showing results (331-340 of 781) with videos related to
Sort By:
Pageof 79
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs in multiple myelomaIrene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, et al.Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.Blood Cancer Journal|January 11, 2023
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2013
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cellsJooeun Bae, Aditya Munshi, Cheng Li, et al.Leukemia & Lymphoma|May 20, 2009
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaJacob P Laubach, Constantine S Mitsiades, Aldo M Roccaro, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|December 15, 2010
Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myelomaSacha N Uljon, Paul G Richardson, Peter H Schur, et al.Leukemia & Lymphoma|June 15, 2017
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'Matthew Ho Zhi Guang, Amanda McCann, Giada Bianchi, et al.Oncogene|September 19, 2003
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Martin Sattler, et al.Hematology. American Society of Hematology. Education Program|November 10, 2001
Multiple Myeloma: New Insights and Therapeutic ApproachesKenneth C. Anderson, Robert A. Kyle, William S. Dalton, et al.Haematologica|May 12, 2018
Meaningful changes in end-of-life care among patients with myelomaOreofe O Odejide, Ling Li, Angel M Cronin, et al.Pageof 79